Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jan 20;121(11):e20240695.
doi: 10.36660/abc.20240695. eCollection 2025.

The Choice of Antiplatelet Dual Combination in Coronary Artery Disease: Is this Just a Question of Balance between ischemic Burden and Bleeding Risk?

[Article in Portuguese, English]
Maria Cristina Almeida  1 , Marildes Luiza de Castro  2 , Larissa Neto Espíndola  3
Affiliations
Editorial

The Choice of Antiplatelet Dual Combination in Coronary Artery Disease: Is this Just a Question of Balance between ischemic Burden and Bleeding Risk?

[Article in Portuguese, English]
Maria Cristina Almeida et al. Arq Bras Cardiol. .
No abstract available

PubMed Disclaimer

Figures

Figura 1
Figura 1. Escolha da dupla antigregação plaquetária (DAPT): o desafio está em equilibrar a prevenção dos eventos isquêmicos com o risco de sangramento. IAMCST: Infarto agudo do miocárdio com elevação do segmento ST; AVC: acidente vascular cerebral.
Figura 2
Figura 2. Escores de risco: risco de isquemia e de sangramento.
Figure 1
Figure 1. Dual antiplatelet therapy (DAPT) choice: the challenge lies in balancing the prevention of ischemic events with the risk of bleeding; STEMI: ST-elevation myocardial infarction.
Figure 2
Figure 2. Risk scores: ischemic risk and bleeding risk.
See this image and copyright information in PMC

References

    1. Vrints C, Andreotti F, Koskinas KC, Rosselo X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes Developed by the Task Force for the Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC) Eur Heart J. 2024;45(36):1–123. doi: 10.1093/eurheartj/ehae177. - DOI - PubMed
    1. Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, et al. Dual Antiplatelet Therapy after Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation. 2020;142(15):1425–1436. doi: 10.1161/CIRCULATIONAHA.120.046308. - DOI - PMC - PubMed
    1. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2018;39(3):213–260. doi: 10.1093/eurheartj/ehx419. - DOI - PubMed
    1. Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, et al. Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions. JACC Cardiovasc Interv. 2024;17(19):2197–2215. doi: 10.1016/j.jcin.2024.08.022. - DOI - PubMed
    1. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632–2653. doi: 10.1093/eurheartj/ehz372. - DOI - PMC - PubMed

Publication types

LinkOut - more resources